* 1. neurological disorders prior to covid-19 diagnosis * 2. with pre-existing terminal illness * 3. with known immune disease * 4. is pregnant or breastfeeding * 5. is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening * 6. has received any vaccination within 3 weeks prior to the first ip infusion * 7. judged by the investigator to be not suitable for study participation * 8. under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

* 1. neurological disorders prior to covid-19 diagnosis * 2. with pre-existing terminal illness * 3. with known immune disease * 4. is pregnant or breastfeeding * 5. is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening * 6. has received any vaccination within 3 weeks prior to the first ip infusion * 7. judged by the investigator to be not suitable for study participation * 8. under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

1. neurological disorders prior to covid-19 diagnosis 2. with pre-existing terminal illness 3. with known immune disease 4. is pregnant or breastfeeding 5. is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening 6. has received any vaccination within 3 weeks prior to the first ip infusion 7. judged by the investigator to be not suitable for study participation 8. under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

1. neurological disorders prior to covid-19 diagnosis 2. with pre-existing terminal illness 3. with known immune disease 4. is pregnant or breastfeeding 5. is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening 6. has received any vaccination within 3 weeks prior to the first ip infusion 7. judged by the investigator to be not suitable for study participation 8. under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters